CIK 0001597553
SAGE Sage Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 31, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Sage Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 47 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2025 | Elizabeth A. Barrett director | UTender of shares Common Stock | -3,000 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Christopher Benecchi Chief Operating Officer | DDisposition to issuer Common Stock | -28,053 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Geno J Germano director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Jessica Federer director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Michael F Cola director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | James M Frates director | UTender of shares Common Stock | -2,845 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Elizabeth A. Barrett director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | James M Frates director | DDisposition to issuer Stock Option (Right to Buy)derivative | -19,154 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Christopher Benecchi Chief Operating Officer | DDisposition to issuer Common Stock | -36,375 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | James M Frates director | DDisposition to issuer Stock Option (Right to Buy)derivative | -21,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Christopher Benecchi Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,500 | - | - | 0 | Jul 31, 2025 |
| Jul 31, 2025 | Christopher Benecchi Chief Operating Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -40,000 | - | - | 0 | Jul 31, 2025 |
| Jun 24, 2025 | Michael C. Quirk See Remarks | FTax withholding Common Stock | -113 | $9.22 | $1,042 | 30,461 | Jun 26, 2025 |
| Jun 24, 2025 | Gregory L. Shiferman See Remarks | FTax withholding Common Stock | -79 | $9.22 | $728 | 30,950 | Jun 26, 2025 |
| Jun 11, 2025 | Michael F Cola director | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Jun 11, 2025 | George Golumbeski director | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Jun 11, 2025 | Geno J Germano director | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Jun 11, 2025 | Jessica Federer director | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Jun 11, 2025 | James M Frates director | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Jun 11, 2025 | Elizabeth A. Barrett director | AGrant or award Stock Option (Right to Buy)derivative | +21,500 | $0.00 | $0 | 21,500 | Jun 13, 2025 |
| Apr 10, 2025 | Christopher Benecchi Chief Operating Officer | AGrant or award Common Stock | +3,255 | $0.00 | $0 | 47,170 | Apr 11, 2025 |
| Apr 10, 2025 | Barry E Greene President and CEO | AGrant or award Common Stock | +19,964 | $0.00 | $0 | 105,031 | Apr 11, 2025 |
| Apr 10, 2025 | Michael C. Quirk See Remarks | AGrant or award Common Stock | +933 | $0.00 | $0 | 30,041 | Apr 11, 2025 |
| Apr 10, 2025 | Gregory L. Shiferman See Remarks | AGrant or award Common Stock | +525 | $0.00 | $0 | 31,205 | Apr 11, 2025 |
| Apr 10, 2025 | Christopher Benecchi Chief Operating Officer | FTax withholding Common Stock | -793 | $6.91 | $5,480 | 46,377 | Apr 11, 2025 |
| Apr 10, 2025 | Barry E Greene President and CEO | FTax withholding Common Stock | -4,862 | $6.91 | $34k | 100,169 | Apr 11, 2025 |
| Apr 10, 2025 | Michael C. Quirk See Remarks | FTax withholding Common Stock | -312 | $6.91 | $2,156 | 29,729 | Apr 11, 2025 |
| Apr 10, 2025 | Gregory L. Shiferman See Remarks | FTax withholding Common Stock | -176 | $6.91 | $1,216 | 31,029 | Apr 11, 2025 |
| Apr 10, 2025 | Christopher Benecchi Chief Operating Officer | AGrant or award Common Stock | +2,712 | $0.00 | $0 | 49,089 | Apr 11, 2025 |
| Apr 10, 2025 | Michael C. Quirk See Remarks | AGrant or award Common Stock | +1,269 | $0.00 | $0 | 30,998 | Apr 11, 2025 |
| Apr 10, 2025 | Christopher Benecchi Chief Operating Officer | FTax withholding Common Stock | -661 | $6.91 | $4,568 | 48,428 | Apr 11, 2025 |
| Apr 10, 2025 | Michael C. Quirk See Remarks | FTax withholding Common Stock | -424 | $6.91 | $2,930 | 30,574 | Apr 11, 2025 |
| Apr 1, 2025 | Michael C. Quirk See Remarks | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 29,108 | Apr 2, 2025 |
| Apr 1, 2025 | Michael C. Quirk See Remarks | AGrant or award Sderivative | +4,000 | $0.00 | $0 | 4,000 | Apr 2, 2025 |
| Feb 13, 2025 | Christopher Benecchi Chief Operating Officer | FTax withholding Common Stock | -822 | $7.18 | $5,902 | 43,915 | Feb 14, 2025 |
| Feb 13, 2025 | Laura Gault Chief Medical Officer | FTax withholding Common Stock | -685 | $7.18 | $4,918 | 34,649 | Feb 14, 2025 |
| Jan 16, 2025 | Christopher Benecchi Chief Operating Officer | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 44,737 | Jan 21, 2025 |
| Jan 16, 2025 | Laura Gault Chief Medical Officer | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 35,334 | Jan 21, 2025 |
| Jan 16, 2025 | Barry E Greene President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +174,000 | $0.00 | $0 | 174,000 | Jan 21, 2025 |
| Jan 16, 2025 | Christopher Benecchi Chief Operating Officer | AGrant or award Stock Options (Right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jan 21, 2025 |
| Jan 3, 2025 | James M Frates director | AGrant or award Stock Options (Right to buy)derivative | +19,154 | $0.00 | $0 | 19,154 | Jan 6, 2025 |
| Jan 3, 2025 | George Golumbeski director | AGrant or award Stock Options (Right to buy)derivative | +13,593 | $0.00 | $0 | 13,593 | Jan 6, 2025 |
| Dec 24, 2024 | Gregory L. Shiferman See Remarks | FTax withholding Common Stock | -79 | $5.48 | $433 | 19,888 | Dec 27, 2024 |
| Nov 1, 2024 | Christopher Benecchi Chief Operating Officer | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 24,737 | Nov 14, 2024 |
| Nov 1, 2024 | Christopher Benecchi Chief Operating Officer | AGrant or award Stock Option (Right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Nov 14, 2024 |
| Nov 1, 2024 | Gregory L. Shiferman See Remarks | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 19,967 | Nov 1, 2024 |
| Nov 1, 2024 | Gregory L. Shiferman See Remarks | AGrant or award Stock Option (Right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 1, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Elizabeth A. Barrettceo, officer, director
- Christopher BenecchiChief Operating Officer
- Michael F Coladirector
- James M Fratescfo, officer, director
- Jessica Federerdirector
- Laura GaultChief Medical Officer
- Geno J Germanodirector
- George Golumbeskidirector
- Barry E GreenePresident and CEO
- Michael C. QuirkSee Remarks
- Gregory L. ShifermanSee Remarks
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.